PITTSBURGH — Mylan N.V. has launched clindamycin palmitate hydrochloride oral solution 75 mg/5 ml, an antibiotic, in the United States.

Mylan said Friday that its product is a generic version of Cleocin solution by Pharmacia/Upjohn (Pfizer) .

Mylan received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for the product, indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci, when less toxic alternatives are inappropriate.

Clindamycin palmitate hydrochloride oral solution (75 mg/5 ml) totaled U.S. sales of approximately $30.9 million for the 12 months ended March 31, according to IMS Health data reported by Mylan.